Physician profile
Ashwin Kashyap
NPI 1861495475
$2,669.69
in general payments reported to CMS, 2019-2025
24 companies · $63.37 in 2025
The $63.37 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,813 · 2020: $408 · 2021: $54.64 · 2022: $99.83 · 2023: $80.92 · 2024: $151 · 2025: $63.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $163 · Food and Beverage: $132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $163.36 |
| Food and Beverage | $131.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $434.70 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $432.41 | 2019-2022 | |
| Genentech USA, INC. | $300.95 | 2019-2020 | |
| Janssen Biotech, INC. | $197.62 | 2019-2020 | |
| Seagen INC. | $195.33 | 2019-2022 | |
| Celgene Corporation | $189.20 | 2019-2024 | Reblozyl |
| Amgen INC. | $186.89 | 2019-2025 | |
| Aurobindo Pharma USA, INC. | $103.36 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $91.98 | 2019-2020 | |
| Foundation Medicine, INC. | $80.92 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $64.56 | 2019-2022 | |
| Karyopharm Therapeutics INC. | $56.43 | 2020-2021 | |
| Abbvie INC. | $40.49 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $40.26 | 2019-2021 | |
| Eisai INC. | $38.18 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.30 | 2019-2020 | |
| Clovis Oncology, INC. | $28.44 | 2019 | |
| Astellas Pharma US INC | $25.00 | 2019 | |
| Genzyme Corporation | $24.87 | 2019 | |
| Alexion Pharmaceuticals, INC. | $24.75 | 2019 | |
| Janssen Pharmaceuticals, INC | $22.79 | 2019 | |
| Secura Bio, INC. | $22.07 | 2019 | |
| Rigel Pharmaceuticals, INC. | $21.36 | 2019 | |
| Medtronic USA, INC. | $17.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashwin Kashyap listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.